GPP
CERE

Great Point Partners’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Great Point Partners’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-215,000
Closed -$4.69M – 48
2023
Q3 		$4.69M Buy
+215,000
New +$5.38M 0.85% 34

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Great Point Partners's CERE Position: Q4 2023 in Review

Great Point Partners sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2023, closing a stake of 215,000 shares — an estimated $4.69M sold.

Great Point Partners first reported a position in CERE in Q3 2023 and held it in 1 quarter. The position peaked at $4.69M in Q3 2023. 195 funds tracked by Wall St. Rank hold CERE as of Q4 2023.

  • Great Point Partners reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Great Point Partners sold 215,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2023, an estimated $4.69M.
  • Great Point Partners first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • Great Point Partners's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $4.69M in Q3 2023.
  • 195 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2023.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.